USE OF A LABORATORY MODEL WITH HUMAN SUBJECTS

使用人类受试者的实验室模型

基本信息

  • 批准号:
    6576878
  • 负责人:
  • 金额:
    $ 17.12万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-04-01 至 2002-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: This proposal requests funding to use a laboratory model with human research subjects to test the impact of immunization on cocaine?s effects and on cocaine use. The widespread use of cocaine, its role in the spread of diseases such as AIDS, its use by pregnant women to the detriment of themselves and their offspring, as well as the multiplicity of cocaine?s other deleterious effects, makes imperative the control of this severe public health problem. Although behavioral interventions are a necessary module of any treatment intervention, and successes have been reported, the extraordinary reinforcing efficacy of cocaine increases the likelihood that behavioral interventions alone will be insufficient to adequately impact a substantial percentage of cocaine abusers. It is clear that other therapeutic approaches will have to be combined with behavioral therapy if most cocaine abusers are to be successfully treated. This protocol would test the hypothesis that immunization followed by adequate antibody titers will result in changes in response to cocaine such that the likelihood of cocaine use will decrease substantially. Specifically, two studies would be executed: (1) The first would compare the subjective and physiological response of research subjects to intravenous doses of cocaine before and after immunization. (2) The second would evaluate, within the context of a cocaine choice/self-administration protocol, the effects of immunization on cocaine craving, on the choice to take cocaine, and on cocaine?s other subjective and physiological effects. Specifically, the following questions are posed: 1) Are there changes in cocaine?s physiological and subjective effects (including measures of cocaine craving) measured after single doses of cocaine that are the result of immunization? Non-treatment-seeking cocaine-using volunteers will be tested before and after immunization when antibody titers are considered sufficient. Cocaine dose-response functions will be collected and blood levels of cocaine and its metabolites would be monitored under both conditions. 2) Does immunization, with sufficient antibody titers, result in reduced cocaine use? The PL?s cocaine self-administration/choice procedure is one in which non-treatment-seeking cocaine-using volunteers are given the opportunity to take repeated doses of cocaine under carefully controlled conditions before and after immunization. Measures would also be made of cocaine?s physiological and subjective effects and volunteers would have the opportunity to self-administer cocaine in doses and patterns seen in the natural ecology. The opportunity for a ?mini-binge? would be used to make it possible to generalize from these data to cocaine users outside of the laboratory and to provide support for taking this therapy to a large-scale clinical trial.
描述:

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARIAN W FISCHMAN其他文献

MARIAN W FISCHMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARIAN W FISCHMAN', 18)}}的其他基金

AMANTADINE AS POTENTIAL TREATMENT FOR COCAINE ABUSE
金刚烷胺作为可卡因滥用的潜在治疗方法
  • 批准号:
    6567821
  • 财政年份:
    2001
  • 资助金额:
    $ 17.12万
  • 项目类别:
COCAINE EFFECTS IN HUMANS--PHYSIOLOGY AND BEHAVIOR
可卡因对人类的影响——生理和行为
  • 批准号:
    6567761
  • 财政年份:
    2001
  • 资助金额:
    $ 17.12万
  • 项目类别:
SCHERING SCH 39166 AS TREATMENT FOR COCAINE ABUSE IN HUMANS
先灵 SCH 39166 用于治疗人类可卡因滥用
  • 批准号:
    6567804
  • 财政年份:
    2001
  • 资助金额:
    $ 17.12万
  • 项目类别:
IV COCAINE ABUSE TREATMENT--A LABORATORY MODEL
静脉注射可卡因滥用治疗——实验室模型
  • 批准号:
    6567772
  • 财政年份:
    2001
  • 资助金额:
    $ 17.12万
  • 项目类别:
VENLAFAXINE AS TREATMENT FOR COCAINE ABUSE IN HUMANS
文拉法辛治疗人类可卡因滥用
  • 批准号:
    6567793
  • 财政年份:
    2001
  • 资助金额:
    $ 17.12万
  • 项目类别:
GABAPENTIN AS PHARMACOTHERAPY FOR COCAINE ABUSE
加巴喷丁作为可卡因滥用的药物治疗
  • 批准号:
    6567741
  • 财政年份:
    2001
  • 资助金额:
    $ 17.12万
  • 项目类别:
IV COCAINE ABUSE TREATMENT--A LABORATORY MODEL
静脉注射可卡因滥用治疗——实验室模型
  • 批准号:
    6468511
  • 财政年份:
    2000
  • 资助金额:
    $ 17.12万
  • 项目类别:
LABORATORY MODEL FOR HEROIN ABUSE MEDICATIONS
海洛因滥用药物的实验室模型
  • 批准号:
    6340807
  • 财政年份:
    2000
  • 资助金额:
    $ 17.12万
  • 项目类别:
COCAINE EFFECTS IN HUMANS--PHYSIOLOGY AND BEHAVIOR
可卡因对人类的影响——生理和行为
  • 批准号:
    6468501
  • 财政年份:
    2000
  • 资助金额:
    $ 17.12万
  • 项目类别:
SCHERING SCH 39166 AS TREATMENT FOR COCAINE ABUSE IN HUMANS
先灵 SCH 39166 用于治疗人类可卡因滥用
  • 批准号:
    6468542
  • 财政年份:
    2000
  • 资助金额:
    $ 17.12万
  • 项目类别:

相似海外基金

Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
  • 批准号:
    9981001
  • 财政年份:
    2017
  • 资助金额:
    $ 17.12万
  • 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
  • 批准号:
    9751102
  • 财政年份:
    2017
  • 资助金额:
    $ 17.12万
  • 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
  • 批准号:
    9397073
  • 财政年份:
    2017
  • 资助金额:
    $ 17.12万
  • 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
  • 批准号:
    10223410
  • 财政年份:
    2017
  • 资助金额:
    $ 17.12万
  • 项目类别:
PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-BETA (REBI
使用 SC IFN-β (REBI) 预防 MS 患者中和抗体形成
  • 批准号:
    7951676
  • 财政年份:
    2008
  • 资助金额:
    $ 17.12万
  • 项目类别:
PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-β-AL
预防 SC IFN- 多发性硬化症患者中和抗体的形成
  • 批准号:
    7606036
  • 财政年份:
    2006
  • 资助金额:
    $ 17.12万
  • 项目类别:
IMMUNOLOGIC MECHANISM OF INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA
血友病抑制剂抗体形成的免疫学机制
  • 批准号:
    7375053
  • 财政年份:
    2005
  • 资助金额:
    $ 17.12万
  • 项目类别:
IMMUNOLOGIC MECHANISM OF INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA
血友病抑制剂抗体形成的免疫学机制
  • 批准号:
    7201220
  • 财政年份:
    2004
  • 资助金额:
    $ 17.12万
  • 项目类别:
Immunologic Mechanism of Inhibitor Antibody Formation in Hemophilia
血友病抑制剂抗体形成的免疫学机制
  • 批准号:
    6980810
  • 财政年份:
    2003
  • 资助金额:
    $ 17.12万
  • 项目类别:
INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA AND VON WILLEBRAND'S DISEASE
血友病和冯·维勒布兰德病中的抑制剂抗体形成
  • 批准号:
    6419444
  • 财政年份:
    2000
  • 资助金额:
    $ 17.12万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了